Overview

Update
Total Equity Funding
$86.5M in 4 Rounds from 6 Investors
Most Recent Funding
$4.5M Series E on March 19, 2016
Headquarters:
South San Francisco, CA
Description:
CoMentis is a biotech company engaged in the research and development of small molecule drugs to treat neurovascular diseases.
Categories:
Health Care, Biotechnology, Medical
Website:
http://www.comentis.com
Social:

Company Details

Update

CoMentis is a biotech company focused on the research and development of small molecule drugs to treat neurovascular diseases such as Alzheimer's disease (AD), age-related macular degeneration (AMD) and other cognitive disorders. Originally founded in 2004 as Athenagen, Inc., the company was re-named CoMentis following its August 2006 merger with Zapaq, Inc., which created a leading neurovascular disease franchise.

Funding Rounds (4) - $86.5M

Update
DateAmount / RoundValuationLead InvestorInvestors
Mar, 2016$4.5M / Series E0
Jun, 2008$20M / Series D0
Dec, 2007$12M / Series C1
Sep, 2006$50M / Series B5

Board Members and Advisors (1)

Update

Offices/Locations (1)

Update
  • Corporate Headquarters

    280 Utah Avenue, Suite 275

    South San Francisco, CA 94080

    USA

Past Team (2)

Update

Images (1)

Update

Add Acquisitions

Add Current Team

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos